Cargando…

免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展

With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143967/
https://www.ncbi.nlm.nih.gov/pubmed/33819969
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04
_version_ 1783696863495454720
collection PubMed
description With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations.
format Online
Article
Text
id pubmed-8143967
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-81439672021-05-26 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展 Zhongguo Fei Ai Za Zhi 综述 With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations. 中国肺癌杂志编辑部 2021-03-20 /pmc/articles/PMC8143967/ /pubmed/33819969 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https: //creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) .
spellingShingle 综述
免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title_full 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title_fullStr 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title_full_unstemmed 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title_short 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
title_sort 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143967/
https://www.ncbi.nlm.nih.gov/pubmed/33819969
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04
work_keys_str_mv AT miǎnyìjiǎnchádiǎnyìzhìjìzàiqūdòngjīyīnyángxìngwǎnqīfēixiǎoxìbāofèiáizhōngdeyīngyòngjìnzhǎn
AT miǎnyìjiǎnchádiǎnyìzhìjìzàiqūdòngjīyīnyángxìngwǎnqīfēixiǎoxìbāofèiáizhōngdeyīngyòngjìnzhǎn